HSBC Holdings’s Avita Medical RCEL Stock Holding History

HSBC Holdings’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,183	Closed	-$52.2K	–	3121
2025 Q3	$52.2K	Buy	+10,183	New	+$53.1K	﹤0.01%	2645

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HSBC Holdings's RCEL Position: Q4 2025 in Review

HSBC Holdings sold out of Avita Medical (RCEL) in Q4 2025, closing a stake of 10,183 shares — an estimated $52.2K sold.

HSBC Holdings first reported a position in RCEL in Q3 2025 and held it in 1 quarter. The position peaked at $52.2K in Q3 2025. 67 funds tracked by Wall St. Rank hold RCEL as of Q4 2025.

HSBC Holdings reported no remaining Avita Medical position as of Q4 2025 after selling out during the quarter.
HSBC Holdings sold 10,183 Avita Medical shares in Q4 2025, an estimated $52.2K.
HSBC Holdings first reported a position in Avita Medical in Q3 2025 and held it in 1 quarter.
HSBC Holdings's Avita Medical position peaked at $52.2K in Q3 2025.
67 funds tracked by Wall St. Rank held Avita Medical as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.